VERAXA Biotech (NASDAQ: VRXA) is broadening its reliance on human-relevant preclinical testing methods across its antibody-based cancer drug development programs, a strategic shift that could enhance the predictive value of early research while cutting down on animal use. The company is implementing New Approach Methodologies (NAMs), including three-dimensional tumor spheroid models and patient-derived tumor models, to support its BiTAC(R) T-cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bsADCs). The move matters because traditional animal models often fail to accurately predict human responses, leading to costly late-stage failures. By adopting NAMs, VERAXA aims to generate data that better reflects human biology, potentially accelerating the path to clinical trials and improving success rates.
In a recent ex vivo study, VERAXA’s lead BiTAC T-cell engager demonstrated selective and potent T-cell-mediated killing of tumor cells across 10 patient-derived non-small cell lung cancer models, with relevant controls showing minimal activity. Notably, the study required approximately 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. This dramatic reduction in animal use underscores the efficiency of NAMs and aligns with growing regulatory and ethical pressures to minimize animal testing. The findings also support VERAXA’s dual-targeting approach, which directs immune activity toward cancer cells expressing two selected targets, and its broader strategy of integrating human-relevant models into preclinical research. For investors, this announcement signals VERAXA’s commitment to innovative, efficient drug development, which could translate into faster timelines and lower costs. The company’s focus on NAMs may also position it favorably amid increasing regulatory acceptance of such methods. VERAXA was founded on scientific breakthroughs at the European Molecular Biology Laboratory and is advancing a pipeline of ADCs and proprietary BiTAC formats. For more details, visit the VERAXA Biotech (NASDAQ: VRXA) profile or view the full article. Regular updates are available at https://investors.veraxa.com, and news is also available at https://ibn.fm/VRXA. The announcement was distributed through InvestorWire, part of the IBN network.
